Contact :

Dr François CAILLER, CEO

Research Areas:

SurgiMAb develops injectable fluorescent conjugates to be used during Fluorescence-Guided Surgery (FGS) by oncology surgeons so they can clearly delineate tumors and visualize infra-clinical size nodules invisible to their naked eyes. The efficacy of SGM-101 was demonstrated in the clinical studies performed so far.

Skills / Know-how:

• Design an development of antibody-dye conjugates for in vivo fluorescence imaging
• Preclinical studies
• Clinical trials

Location :

Immeuble Cap Delta
ZAC Euromédecine II
1682 rue de la Valsière
34790 Grabels – FRANCE

 Website : www.surgimab.com